

4 June 2020

### Availability of Creon (Pancreatin) 25K

Mylan, the marketing authorisation holder for Creon in the UK, is experiencing a temporary supply constraint of Creon 25K.

We are working closely with our wholesale partners to ensure an even distribution nationally of stock available, but some areas of the UK may experience supply constraints during the month of June. We anticipate normal stock levels to resume at the end of June.

Creon Micro and Creon 10K continue to be available. Dosing of Creon is based on lipase units. Patients prescribed Creon 25K can reach their recommended amount by taking more of the lower strength capsules (Creon 10K) and should not be concerned about the efficacy when transferring to lower strength capsules to achieve their prescribed dosage.

We are working closely with patient advocacy groups to ensure they are informed of the temporary supply constraint and will continue to keep our dedicated website, [www.creon.co.uk](http://www.creon.co.uk), updated with the latest stock information.

### **Information for Patients and Prescribers**

Mylan is unable to make any specific treatment recommendations to healthcare professionals or for individual patients, however, it is recommended that patients speak to their treating physician to discuss treatment options according to their health needs and their relevant clinical history.

### **About Creon**

Creon is a Pancreatic Enzyme Replacement Therapy (PERT) that helps patients with Pancreatic Exocrine Insufficiency (PEI) to break down food and digest nutrients by replacing the pancreatic enzymes made by a healthy pancreas. The active substance of Creon is pancreatin, a natural substance from the pancreas of the pig; as a biologic product Creon is produced using a complex manufacturing process that is subject to high standards and strict requirements in terms of quality and compliance.

### **Contact Information**

If you require additional information or have any questions, please contact our medical information team on 01707 853 000 or via email; [info.uk@mylan.co.uk](mailto:info.uk@mylan.co.uk)

Adverse events should be reported. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). By reporting side effects you can help provide more information on the safety of this medicine. You should also inform the company who markets Creon in the UK directly via [ukpharmacovigilance@mylan.com](mailto:ukpharmacovigilance@mylan.com) or [+44 \(0\)800 121 8267](tel:+44208001218267).